Template File: /srv/users/serverpilot/apps/emquire/public/wp-content/themes/emquire2017/single-project.php | Template Hierarchy
WP version: 5.1.1
PHP version 7.1.30
There exists continued controversy over the use of propofol in ED PSA, this is despite its widespread existence in clinical practice for at least a decade. These concerns are not limited to the ED setting and are primarily related to the pharmacological properties of the drug itself and its potential for harm. The bolus administration of propofol, aimed at a target of sedation, offers several advantages over more traditional agents, yet these advantages are also its limitations. The use of a target-controlled infusion may provide the seditionist with greater control over the pharmacokinetics of propofol and thus reduce the rate of adverse incident. This study aims to use a pragmatic design to test the safety and efficacy of propofol TCI against usual PSA care in the ED.
Nicola was our first nurse appointed smashing the interview and rapidly getting a handle on the intricacies of clinical research in the ED. Her portfolio of studies includes She leads on Rapid-CTCA, Target-CTCA, SABER and Pro Teds
Mark was appointed in June 2017 and has rapidly found his feet helping promote QEUH ED nurse engagement. His infectious enthusiasm and energy will be a huge asset to the team! He leads on Novel, Aerogen, RAMPP, Frontiers
Introducing Dave the Trauma Man! The QEUH will become a Major Trauma Centre in 2019 as part of the Scottish Trauma Network. Dave is going to have a pretty tough year… in fact he is going to experience more car accidents, falls from height and industrial accidents than any other manikin in Scotland.